clinical trial · NCT05775523

A Post-Authorisation Safety Study (PASS) of Patients Treated With Lonapegsomatropin

Ascendis Pharma Endocrinology Division A/S·—·recruiting·n = 500

Growth Hormone DeficiencyNo intervention

brief summary

The goal of this study is to further characterise the potential long-term safety risks of lonapegsomatropin in patients treated with lonapegsomatropin under real-world conditions in the post-marketing setting.

started

Mar 20, 2023

primary completion

Mar 1, 2033

completion

Mar 1, 2033

last updated

Feb 4, 2026

official title

A Prospective, Non-interventional (NIS), Long-term, Post-Authorisation Safety Study (PASS) of Patients Treated With Lonapegsomatropin

full record on clinicaltrials.gov ↗

sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol